| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3103362
Max Phase: Preclinical
Molecular Formula: C16H23N3O2
Molecular Weight: 289.38
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: Cc1ccc(N2CCN(C(=O)N3CCOCC3)CC2)cc1
Standard InChI: InChI=1S/C16H23N3O2/c1-14-2-4-15(5-3-14)17-6-8-18(9-7-17)16(20)19-10-12-21-13-11-19/h2-5H,6-13H2,1H3
Standard InChI Key: YUVYKZDXOQTEHV-UHFFFAOYSA-N
Associated Targets(Human)
Aldo-keto reductase family 1 member C4 224 Activities
Aldo-keto-reductase family 1 member C3 1414 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Aldo-keto reductase family 1 member C2 639 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Aldo-keto reductase family 1 member C1 475 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 289.38 | Molecular Weight (Monoisotopic): 289.1790 | AlogP: 1.57 | #Rotatable Bonds: 1 |
| Polar Surface Area: 36.02 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 3.85 | CX LogP: 1.56 | CX LogD: 1.56 |
| Aromatic Rings: 1 | Heavy Atoms: 21 | QED Weighted: 0.79 | Np Likeness Score: -1.59 |
References
| 1. Flanagan JU, Atwell GJ, Heinrich DM, Brooke DG, Silva S, Rigoreau LJ, Trivier E, Turnbull AP, Raynham T, Jamieson SM, Denny WA.. (2014) Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3)., 22 (3): [PMID:24411201] [10.1016/j.bmc.2013.12.050] |
Source
Source(1):